SecBot SecBot
6-K ·Filed Jun 15, 2026

GMAB

GENMAB A/S
NEUTRAL
Impact 2/10
Horizonmonths Processed5mo ago SEC0001434265-26-000090
Notable filing: 6-K
Actionable Insight • Neutral

This filing is purely administrative with no trading implications. Monitor for any future capital increases or warrant exercises, but the current filing does not alter the company's financial outlook or operations.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$24.58
T+0 close · Jun 15, 2026 · via day close
Latest settled
+34.42%
T+60 · $33.04
Vs SPY
+33.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $24.58entry
  2. T+1 · 5mo ago +0.65%α +1.25% · $24.74
  3. T+5 · 5mo ago +4.19%α +5.57% · $25.61
  4. T+20 · 4mo ago +17.17%α +17.92% · $28.80
  5. T+60 · 2mo ago +34.42%α +33.42% · $33.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Genmab A/S filed its updated Articles of Association via a 6-K on June 15, 2026, reflecting standard corporate governance provisions including share capital details, authorized capital increases, employee warrant programs, and a board indemnification scheme. This is a routine administrative filing with no financial results, material events, or strategic announcements.

Key Facts

  • Share capital is DKK 62,353,067 divided into shares of DKK 1 each.
  • Board authorized until March 12, 2029 to increase share capital by up to DKK 6,600,000 (with or without pre-emption rights).
  • Multiple warrant programs for employees (excluding executive management) with up to DKK 750,000 nominal each, expiring between 2026 and 2030.
  • Board authorized to issue convertible debt instruments up to DKK 3,000,000 nominal until March 12, 2029.
  • Indemnification scheme for board members established through March 12, 2029.

Financial Impact

No material financial impact; routine governance update.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000090
Document: gmab_20260615xx6k.htm0001434265-26-000090
Document: 0001434265-26-000090-index-headers.html0001434265-26-000090
Document: 0001434265-26-000090-index.html0001434265-26-000090
Document: 0001434265-26-000090.txt0001434265-26-000090

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026